Filing Flows › Tonix Pharmaceuticals Holding (TNXP) › Q1 2025
Tonix Pharmaceuticals Holding (TNXP) Q1 2025 earnings results (first quarter 2025)
10-Q filed May 12, 2025
Tonix Pharmaceuticals Holding (TNXP) reported revenue of $2.4M for the first quarter 2025 (Q1 2025), -2% from a year earlier and -6% from the quarter before. Operating margin was -660.9%, net loss $16.8M (692.8% of revenue).
Tonix Pharmaceuticals Holding, Q1 2025: revenue $2.4M (-2% year over year), operating margin -660.9%, net loss $16.8M, operating cash flow −$16.6M. The chart follows the revenue to costs, profit and cash.
| Q1 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $2.4M | -6% | -2% |
| Operating profit | −$16.1M | — | — |
| Net earnings | −$16.8M | — | — |
| Operating cash flow | −$16.6M | — | — |
What changed
Revenue was $2.4M in Q1 2025, down 2% year over year and down 6% from the previous quarter. Zembrace Symtouch was the largest line at 83% of revenue. Tosymra lost $232K year over year (down 37%), 438% of the total change.
Operating costs exceeded revenue by $16.1M, an operating margin of -660.9%. Total costs fell 22% while revenue fell 2%. The quarter ended with a net loss of $16.8M, narrower than the previous quarter's $22.1M loss.
Operating cash flow was −$16.6M. Non-cash charges added back $493K of depreciation and amortization and $882K of share-based compensation. Working capital and other items used $1.1M. Capital expenditures of $6K exceeded it, leaving free cash flow of −$16.6M.
Questions
What was Tonix Pharmaceuticals Holding's revenue in the first quarter 2025?
Tonix Pharmaceuticals Holding (TNXP) reported revenue of $2.4M for the first quarter 2025 (Q1 2025), -2% from a year earlier and -6% from the quarter before.
Was Tonix Pharmaceuticals Holding profitable in the first quarter 2025?
Operating loss was $16.1M (-660.9% of revenue) and net loss $16.8M.